Efficacy and safety of weekly alendronate plus vitamin D₃ versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

Vitamin D (vit-D) is essential for bone health, although many osteoporosis patients have low levels of 25-hydroxy-vit-D [25(OH)D].

Neuromuscular function was also measured.

Who Took Part

According to the abstract, 268 subjects were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, women only.

A total of 268 subjects were randomized.

How the Study Was Run

The design is described as randomized and open-label.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the subjects and staff both knew the treatment.

What Was Measured

Vitamin D (vit-D) is essential for bone health, although many osteoporosis patients have low levels of 25-hydroxy-vit-D [25(OH)D].

Neuromuscular function was also measured.

The subject headings attached to it are Alendronate, Cholecalciferol, Osteoporosis, Postmenopausal and Vitamin D Deficiency.

The authors tagged it with the keywords parathyroid hormone, vitamin-D and vitamin-D insufficiency.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84) in 268 subjects.

The publication is from 2014 (Yonsei medical journal), a journal based in Korea (South).

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.